ELANE
Neutrophil elastase
As of the edition of 20 October 2026, ELANE (neutrophil elastase, UniProt P08246) has 4 drugs tested at it and 7 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08246
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 38
- Disease areas
- Lungs and airways; Digestive system; Inherited and neonatal; Immune system; Infections; Hormones; Nutrition and metabolism; Heart and blood vessels
- Registered trials of its drugs
- 85
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| .alpha.1-proteinase inhibitor human | Marketed | Phase 4 | Ended 1999 |
| Sivelestat | Active | Phase 4 | none listed |
| Alvelestat | Stopped | Phase 2 | none listed |
| POL6014 | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Grifols Therapeutics | Route B |
| CSL Behring | Route B |
| Santhera Pharmaceuticals | Route A |
The other 4 companies at ELANE
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at ELANE, ranked, with the facts behind eachRequest access. Nothing is shown until you do.